New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer

Table 1

Agents targeting AR in clinical development for CRPC.

Drug	Mechanism of action	Patient characteristics	Phase of development	Clinical trial registration number
MDV-3100	AR antagonist	Chemotherapy-treated	Phase III	NCT00974311
		Chemotherapy-naïve	Phase III	NCT01212991
ARN-509	AR antagonist	ND	Phase I-II	NCT01171898
AZD3514	AR antagonist	ND	Phase I-II	NCT01162395
Abiraterone acetate	CYP 17 inhibitor	Chemotherapy-treated	Phase III	NCT00638690
		Chemotherapy-naïve	Phase III	NCT00887198
Orteronel (TAK-700)	CYP 17 inhibitor	Chemotherapy-treated	Phase III	NCT01193257
VN/124-1 (TOK-001)	AR downregulating agent, CYP 17 inhibitor, and AR antagonist	ND	Phase I-II	NCT00959959

ND: not defined.